Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 1;37(2):173-179.
doi: 10.1097/HCO.0000000000000935.

Current and future transcatheter aortic valve replacement valves

Rachel Eikelboom  1 , Ricky Muller Moran  1 , Weiang Yan  1 , Michael Yamashita  1 , Apurva Patel  2 , Michael Reardon  3 , Aaron Spooner  1
Affiliations
Review

Current and future transcatheter aortic valve replacement valves

Rachel Eikelboom et al. Curr Opin Cardiol. .

Abstract

Purpose of review: This review analyzes currently available commercial transcatheter aortic valve replacement (TAVR) valves as well as valves in investigational status and those in preclinical testing. The design features and clinical outcomes of the Edwards SAPIEN S3 and Medtronic Evolut PRO+ are described and compared with highlight clinical circumstances where one may be favoured over the other.

Recent findings: Multiple randomized and nonrandomized trials have compared commercial and investigational TAVR valves. The results of these are summarized and discussed within this review with a focus on how the SAPIEN S3 and Evolut PRO+ both compare to each other as well as various valves in different investigational stages.

Summary: TAVR is an innovative and ground-breaking technology that will forever have revolutionized the management of aortic stenosis. Though the technology and valves themselves have come a long way, further developments are necessary if we are to continue to expand its indications and achieve a safer perioperative experience with more durable valves.

PubMed Disclaimer

References

    1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106:3006–3008.
    1. Figulla HR, Webb JG, Lauten A, Feldman T. The transcatheter valve technology pipeline for treatment of adult valvular heart disease. Eur Heart J 2016; 37:2226–2239.
    1. Loyalka P, Nascimbene A, Metz B, et al. Transcatheter tricuspid valve-in-valve replacement with an Edwards Sapien 3 valve. Tex Heart Inst J 2017; 44:209–213.
    1. Noble S, Myers PO, Hachulla AL, Huber C. Unsuccessful transfemoral tricuspid valve-in-ring implantation: case report and literature review. CJC Open 2019; 26:330–334.
    1. Claessen BE, Tang GHL, Kini AS, Sharma SK. Considerations for optimal device selection in transcatheter aortic valve replacement: a review. JAMA Cardiol 2021; 6:102–112.

Publication types

Grants and funding